Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma - Related Studies

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.

Study NCT00032019. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma

2	Additional conditions recognized in this trial
		Lymphoma, Large-Cell, Immunoblastic
		Lymphoma, Non-Hodgkin

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		cyclophosphamide
		doxorubicin hydrochloride
		etoposide
		filgrastim
		prednisone
		rituximab
		vincristine sulfate

5	Additional drug interventions recognized in this trial
		Doxorubicin
		Vincristine

6	More general drug interventions related to this trial
		Alkylating Agents
		Anti-Inflammatory Agents
		Antibiotics, Antineoplastic
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antineoplastic Agents, Hormonal
		Antineoplastic Agents, Phytogenic
		Antirheumatic Agents
		Glucocorticoids
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses
		Tubulin Modulators

7	Sponsors listed in this trial
		Cancer and Leukemia Group B
		National Cancer Institute (NCI)